Skip to content
Exclusive CEO Interviews

Press Release

Make us preferred on Google
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

✨ Onyx Summary The European Medicines Agency recommended granting conditional marketing authorization for ImmunityBio’s ANKTIVA in combination with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, marking a potential new treatment option where cystectomy is often the only alternative. The recommendation, based on durable complete

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

✨ Onyx Summary Guardant Health and Trial Library formed a strategic collaboration to integrate precision oncology diagnostics with AI-driven trial matching and navigation to expand access to cancer clinical trials across the United States. The partnership links Guardant’s large-scale biomarker and real-world data with Trial Library’s nationwide clinic network

Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain Health Innovation and Baycrest to Advance Breakthrough Neuromodulation Therapy for Alzheimer’s

Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain Health Innovation and Baycrest to Advance Breakthrough Neuromodulation Therapy for Alzheimer’s

✨ Onyx Summary Sinaptica Therapeutics received funding from the Centre for Aging + Brain Health Innovation (CABHI), in partnership with Baycrest, to support development and validation of its personalized, non-invasive neuromodulation system for Alzheimer’s disease. The funding deepens Sinaptica’s collaboration with Baycrest and supports advancement toward clinical readiness and future

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

✨ Onyx Summary Ocugen said CEO and co-founder Dr. Shankar Musunuri will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, where he will discuss the company’s modifier gene therapy platform and its potential applications in inherited retinal and age-related blindness diseases. The presentation, alongside investor

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

✨ Onyx Summary Lexicon Pharmaceuticals announced the publication of preclinical data in the Journal of the Endocrine Society validating Acyl-CoA Synthetase 5 (ACSL5) as a therapeutic target for obesity and chronic weight management, supporting advancement of its investigational oral inhibitor LX9851. The findings, combined with Lexicon’s March 2025 worldwide licensing

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

✨ Onyx Summary Geron presented new ASH 2025 data reinforcing RYTELO (imetelstat) activity in lower-risk MDS and myelofibrosis, including analyses linking early treatment-emergent cytopenias to subsequent hemoglobin gains and transfusion independence in the IMerge program. Updated long-term outcomes from IMerge and biomarker findings from IMbark further support ongoing development of imetelstat

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

✨ Onyx Summary Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial showing that REC-4881, an investigational allosteric MEK1/2 inhibitor, delivered rapid and durable reductions in polyp burden in patients with familial adenomatous polyposis, with effects persisting after treatment cessation. The results represent the first clinical validation

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

✨ Onyx Summary Legend Biotech Corporation reported updated ASH 2025 data showing CARVYKTI® achieved a median progression-free survival of 50.4 months in triple-class-exposed multiple myeloma patients with three prior lines of therapy, with translational analyses indicating stronger immune fitness when used earlier in treatment. The company also presented first-in-human Phase

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

✨ Onyx Summary Lexicon Pharmaceuticals announced that new clinical data from the SOTA-P-CARDIA trial evaluating the effect of sotagliflozin on adipose tissue distribution in non-diabetic patients with HFpEF will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum in December 2025. The presentation adds to prior cardiovascular data on

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

✨ Onyx Summary Guardant Health will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium (Dec. 9–12, 2025) highlighting data across Guardant Reveal and Guardant360 Liquid that evaluate tissue-free, blood-based testing for minimal residual disease detection, treatment response assessment, relapse risk prediction, and breast cancer subtyping from early-stage

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

✨ Onyx Summary Perspective Therapeutics announced that updated safety and preliminary efficacy data from its [212Pb]VMT-α-NET program in advanced SSTR2-expressing neuroendocrine tumors have been accepted for presentation at the ASCO Gastrointestinal Cancers Symposium 2026. The accepted abstract builds on previously reported interim results showing a favorable safety profile and early

VeriSIM Life Wins Prestigious AI in Action Award at Reuters Global Pharma Awards

VeriSIM Life Wins Prestigious AI in Action Award at Reuters Global Pharma Awards

✨ Onyx Summary VeriSIM Life was named the winner of the AI in Action Award at the Reuters Global Pharma Awards 2025 for its BIOiSIM platform, which applies explainable, mechanistic AI to predict human safety, efficacy, and translational outcomes earlier in drug development. The recognition highlights VeriSIM Life’s growing role

MassBio and SCbio launch Drive application for spring cohort

MassBio and SCbio launch Drive application for spring cohort

✨ Onyx Summary MassBio and SCbio opened applications for the Spring 2026 cohort of Drive, a national accelerator for early-stage biotech and biomarker/diagnostic startups, with programs running March 23–May 15, 2026 and an application deadline of January 16, 2026. The announcement reflects continued investment in early scientific founders, building

enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

✨ Onyx Summary enGene Holdings Inc. announced that the U.S. Food and Drug Administration has selected its investigational non-viral gene therapy detalimogene voraplasmid for participation in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program. The selection supports enGene’s commercial-scale manufacturing strategy and regulatory preparation as